Philosophy of Care
Cancer is not a disease that occurs in a vacuum and thus I focus not only on treating the cancer but also on assisting patients with the nutritional, social, emotional, and spiritual issues which are often ignored in modern medicine. I believe strongly in a multidisciplinary team approach to cancer including open lines of communication with both my patients and fellow physicians. Although I employ aggressive cutting edge anti-cancer treatments I am also respectful of and willing to incorporate holistic and alternative medicines into patient care. Ultimately I strive to treat each patient with the same respect and diligence I would an ailing member of my own family.
Dr. Monjazeb has a clinical focus on the treatment of gastrointestinal malignancies (including esophageal cancer), sarcoma, and central nervous system malignancies. He specializes in various radiotherapy techniques including intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT), stereotactic body radiotherapy and high dose rate brachytherapy.
Dr. Monjazeb is a clinician scientist and participates in both clinical and basic science research projects. His basic science research is focused on understanding how the immune system can be harnessed to fight cancer and how radiotherapy can be used to promote anti-tumor immune responses.
4501 X St., G-140
Sacramento, CA 95817
Ph.D., Wake Forest University (Bowman Gray School of Medicine), Winston-Salem, North Carolina, 2003
B.A., UC Berkeley, Berkeley, California, 1997
Select Honors and Awards:
Howard H. Wong Scholarship in Radiation Oncology. American College of Radiation Oncology, 2007
Clinical Honors in Radiation Oncology. Wake Forest University School of Medicine, 2005
M. R. Cooper Scholarship for excellence in Oncology. Wake Forest University School of Medicine, 2005
Pritchard History of Medicine Award. Wake Forest University School of Medicine, 2005
Alpha Omega Alpha (AOA) Medical Honors Society. Wake Forest University School of Medicine, 2004
Select Recent Publications:
Monjazeb AM, Ayala D, Jensen C, Case LD, Bourland JD, Ellis TL, McMullen KP, Chan MD, Tatter SB, Lesser GJ, Shaw EG. A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys.M. 2012 Feb 1;82(2):743-8. Epub 2011 Jan 13.
Yi SK, Mak W, Yang CC, Liu T, Cui J, Chen AM, Purdy JA, Monjazeb AM, Do L. Development of a Standardized Method for Contouring the Lumbosacral Plexus: A Preliminary Dosimetric Analysis of this Organ at Risk Among 15 Patients Treated With Intensity-Modulated Radiotherapy for Lower Gastrointestinal Cancers and the Incidence of Radiation-Induced Lumbosacral Plexopathy. Int J Radiat Oncol Biol Phys. 2012 Feb 17. [Epub ahead of print]
Samuelian JM, Attia AA, Jensen CA, Monjazeb AM, Blackstock AW, Chan MD, Tatter SB, Lesser GJ, Shaw EG. Treatment of hemoptysis associated with aspergilloma using external beam radiotherapy: A case report and literature review. Practical Radiation Oncology 2011 Oct 1(4):279-281.
Sanders AM, Stehle JR, Blanks MJ, Riedlinger G, Kim-Shapiro JW, Monjazeb AM, Adams JM, Willingham MC, Cui Z. Cancer resistance of SR/CR mice in the genetic knockout backgrounds of leukocyte effector mechanisms: determinations for functional requirements. BMC Cancer, 10: 121. 2010
Kim C, Monjazeb AM, Suntharalingam M, Giesinger KR, Blackstock AW. Preoperative versus postoperative chemoradiotherapy in the trimodality management of esophageal cancer. Clin Adv Hematol Oncol, 7(5): 327-333, 342. 2009
Arachidonic acid-induced gene expression in colon cancer cells. Monjazeb AM, High KP, Connoy A, Hart LS, Koumenis C, Chilton FH. Carcinogenesis. Oct;27(10):1950-60. 2006
Monjazeb AM, High KP, Koumenis C, Chilton FH. Inhibitors of arachidonic acid metabolism act synergistically to signal apoptosis in neoplastic cells. Prostaglandins Leukot Essent Fatty Acids, 73(6):463-74. 2005
Monjazeb A, Stanton C, Levine EA. Intussusception secondary to metastasis from a low-grade retroperitoneal liposarcoma. Am Surg, 70(9): 775-8. 2004
Clay CE, Monjazeb A, Thorburn J, Chilton FH, High KP. 15-Deoxydelta12,14-prostaglandin J2-induced apoptosis does not require PPARgamma in breast cancer cells. J Lipid Res, 43(11): 1818-28. 2002
Monjazeb AM, Clay CE, High KP, Chilton FH. Antineoplastic properties of arachidonic acid and its metabolites. Prostaglandins Leukot Essent Fatty Acids, 66(1): 5-12. 2002